Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study

Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study

Abstract Background The study aimed to examine the direct medical cost and impact of tocilizumab (TOZ) versus adalimumab (ADM) and etanercept (ETC) on reducing the levels of two inflammatory markers (e.g., C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) among patients with rheumat...

Full description

Bibliographic Details
Main Authors: Areej S. Albahdal, Amjad M. Alotaibi, Miteb A. Alanazi, Norah Abanmy, Monira Alwhaibi, Yazed AlRuthia
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Tocilizumab
Etanercept
Adalimumab
Arthritis
Rheumatoid
Cost analysis
Online Access:https://doi.org/10.1186/s12962-024-00522-7

Internet

https://doi.org/10.1186/s12962-024-00522-7

Similar Items